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Therapeutic hypothermia is recommended for comatose adults after witnessed outof-hospital cardiac arrest, but data about this intervention in children are limited.
Methods

We conducted this trial of two targeted temperature interventions at 38 children’s
hospitals involving children who remained unconscious after out-of-hospital cardiac
arrest. Within 6 hours after the return of circulation, comatose patients who were
older than 2 days and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0°C) or therapeutic normothermia (target
temperature, 36.8°C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second edition (VABS-II), score of
70 or higher (on a scale from 20 to 160, with higher scores indicating better function),
was evaluated among patients with a VABS-II score of at least 70 before cardiac arrest.
Results

A total of 295 patients underwent randomization. Among the 260 patients with data
that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest,
there was no significant difference in the primary outcome between the hypothermia
group and the normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P = 0.14). Among all the patients with data that
could be evaluated, the change in the VABS-II score from baseline to 12 months
was not significantly different (P = 0.13) and 1-year survival was similar (38% in the
hypothermia group vs. 29% in the normothermia group; relative likelihood, 1.29; 95%
CI, 0.93 to 1.79; P = 0.13). The groups had similar incidences of infection and serious
arrhythmias, as well as similar use of blood products and 28-day mortality.
Conclusions

In comatose children who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant
benefit in survival with a good functional outcome at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; THAPCA-OH ClinicalTrials.gov
number, NCT00878644.)
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O

ut-of-hospital cardiac arrest in
children often results in death or in poor
long-term functional outcome in survivors.1-3 In 2002, two trials involving adults
showed that therapeutic hypothermia improved
neurologic outcomes in comatose survivors after
out-of-hospital cardiac arrest with ventricular fibrillation or ventricular tachycardia.4,5 International guidelines recommend therapeutic hypothermia for adults with out-of-hospital cardiac
arrest who have similar characteristics.6,7 Recently, another trial involving adults after out-of-hospital cardiac arrest showed that therapeutic hypothermia with the use of a target temperature of
33°C, as compared with actively maintained therapeutic normothermia (36°C), did not improve
outcomes.8 The fundamental difference between
this recent trial and the earlier 2002 trials was
the active intervention to prevent fever in the
comparison group of patients who were treated
with normothermia.4,5,8
Published results of randomized trials of
therapeutic hypothermia in children after out-ofhospital cardiac arrest are lacking.9 In observational studies, therapeutic hypothermia has not
been associated with improved outcomes in
children after cardiac arrest.10-12 Moreover, one
trial involving pediatric patients with traumatic
brain injury showed a trend toward increased
mortality in the hypothermia group.13 There are
significant differences between adult and pediatric populations with out-of-hospital cardiac
arrest, and results cannot be generalized between age groups.14 We report results of the
Therapeutic Hypothermia after Pediatric Cardiac
Arrest Out-of-Hospital (THAPCA-OH) trial, which
compared the efficacy of therapeutic hypothermia (target temperature, 33.0°C) with that of
therapeutic normothermia (target temperature,
36.8°C).15,16

Me thods
Study Design and Oversight

This randomized clinical trial, which was conducted in pediatric intensive care units (ICUs) at
38 children’s hospitals in the United States and
Canada, involved children who were admitted
after out-of-hospital cardiac arrest. The rationale,
study design, outcome selection process, protocol
summary, and 12-month pilot vanguard phase
have been described previously.15-17
The trial was funded by the National Heart,
n engl j med 372;20

Lung, and Blood Institute (NHLBI). The protocol
was designed by the first, third, and last authors.
The institutional review board at each participating site and the data coordinating center at the
University of Utah (see the Supplementary Appendix, available with the full text of this article
at NEJM.org) approved the protocol and informedconsent documents.
The site research coordinators listed in the
Supplementary Appendix collected all the data,
and statisticians at the data coordinating center
performed all the analyses. Details of site training, data management, and site monitoring are
provided in the Supplementary Appendix. An
independent data and safety monitoring board
that was appointed by the NHLBI conducted interim safety and efficacy analyses.18 All the authors vouch for the accuracy and completeness
of the submitted data, the third and last authors
vouch for the data management and statistical
analyses, and all the authors vouch for the fidelity of this report to the study protocol, which is
available at NEJM.org.
Patient Population

Children older than 48 hours and younger than
18 years of age were eligible for inclusion in the
study if they had a cardiac arrest requiring chest
compressions for at least 2 minutes and remained
dependent on mechanical ventilation after the
return of circulation. Major exclusion criteria
were the inability to undergo randomization for
any reason within 6 hours after the return of circulation, a score of 5 or 6 on the Glasgow Coma
Scale motor-response subscale (on which scores
range from 1 to 6, with lower scores indicating
reduced levels of function), the decision by the
clinical team to withhold aggressive treatment,
and major trauma associated with the cardiac
arrest. A full listing of the exclusion criteria is
provided in the Supplementary Appendix. Written
informed consent from a parent or legal guardian was obtained for each participant.
Randomization and Intervention

Eligible patients were randomly assigned in a 1:1
ratio to either therapeutic hypothermia or therapeutic normothermia. Randomization was performed with the use of permuted blocks stratified according to clinical center and age at entry
(<2 years, 2 to <12 years, and ≥12 years).
Targeted temperature management was actively maintained for 120 hours in each group.
nejm.org
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Children who were assigned to therapeutic hypothermia were pharmacologically paralyzed and
sedated, and a Blanketrol III temperature management unit (Cincinnati Sub-Zero) was used,
with blankets applied anteriorly and posteriorly,
to achieve and maintain a core temperature of
33.0°C (range, 32.0 to 34.0) for 48 hours. The
children were then rewarmed over a period of 16
hours or longer to a target temperature of 36.8°C
(range, 36.0 to 37.5); this temperature was actively maintained throughout the remainder of
the 120-hour intervention period. Children who
were randomly assigned to therapeutic normothermia received identical care except that the
core temperature was actively maintained with
the cooling unit at 36.8°C (range, 36.0 to 37.5)
for 120 hours.
Dual monitoring of the central temperature
(esophageal, rectal, or bladder temperature) and
an automatic mode on the temperature management unit were used for all the patients. The
probe connected to the cooling unit was designated to be the primary probe; the other probe
was connected to the bedside monitor for safety
backup. In three patients who received extracorporeal membrane oxygenation (ECMO) at the
time of randomization, ECMO was used for temperature control. All other aspects of clinical care
were determined by the clinical teams.
Outcomes

The primary outcome was survival with a good
neurobehavioral outcome at 12 months of follow-up. A good neurobehavioral outcome was
defined as an age-corrected standard score of
70 or higher on a scale of 20 to 160 on the Vineland Adaptive Behavior Scales, second edition
(VABS-II).19 The VABS-II has an age-corrected
mean score of 100 and a standard deviation of
15; higher scores indicate better function. The
VABS-II data were collected centrally at the Kennedy Krieger Institute by means of telephone
interviews conducted by a trained interviewer
who was unaware of the treatment assignments.
As prespecified in the trial protocol, enrolled
children whose reported VABS-II scores were
less than 70 before cardiac arrest (on the basis
of data from a standardized caregiver questionnaire completed by a parent or guardian at each
site within 24 hours after randomization) were
not included in the primary efficacy analysis.
1900
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Figure 1 (facing page). Enrollment, Randomization,
and Treatment.
Scores on the Glasgow Coma Scale (GCS) motor-response
subscale range from 1 to 6, with lower scores indicating
reduced levels of function. Scores on the Pediatric Overall Performance Category (POPC) and Pediatric Cerebral
Performance Category (PCPC) scales range from 1 to 6,
with lower scores indicating less disability. Scores on
the Vineland Adaptive Behavior Scales, second edition
(VABS-II), range from 20 to 160, with higher scores indicating better function. CNS denotes central nervous
system, ICU intensive care unit, ITT intention to treat,
and THAPCA Therapeutic Hypothermia after Pediatric
Cardiac Arrest.

Patients for whom no baseline VABS-II score was
available were considered to be eligible for the
primary analysis if the baseline Pediatric Overall
Performance Category (POPC) and Pediatric Cerebral Performance Category (PCPC) scores20
were in the normal or mild disability category.17,21 Both scales range from 1 to 6, with lower
scores indicating less disability; patients with
scores of either 1 or 2 on both scales were eligible for the primary analysis.
Secondary outcomes were survival 12 months
after cardiac arrest and change in neurobehavioral function, measured as the difference between the baseline level before cardiac arrest
and the 12-month measurement on the VABS-II.
For the latter, patients who had died and patients with the lowest possible VABS-II score
were assigned the worst possible outcomes, regardless of baseline function.
A global cognitive score that was based on
results of on-site neuropsychological testing was
a tertiary outcome (see the Supplementary Appendix). Safety outcomes included the incidences of blood-product use, infection, and serious
arrhythmias through 7 days and 28-day mortality. Details of the methods used for the assessment of outcomes are provided in the Supplementary Appendix.
Statistical Analysis

The target sample size was calculated on the basis of an absolute effect size of 15 to 20%, with
an estimated primary outcome rate of 15 to 35%
in the normothermia group. Assuming that 5%
of the patients would be excluded owing to a
baseline neurologic deficit and that 5% of patients would be lost to follow-up, we estimated
that 276 patients would need to be enrolled to
nejm.org
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1355 Patients met the inclusion criteria
880 Were excluded owing to one or several exclusion criteria
254 Could not undergo randomization ≤6 hr after return of
circulation
208 Had a clinical team that decided to withhold aggressive
treatment
194 Had GCS motor-response score of 5 or 6
178 Had cardiac arrest with severe brain, thoracic, or abdominal
trauma
66 Had active and refractory severe bleeding
41 Had preexisting terminal illness with life expectancy <12 mo
29 Received continuous epinephrine infusion or norepinephrine
infusion at high doses (≥2 µg/kg/min) just before
randomization
28 Had non–English-speaking or non–Spanish-speaking parent
16 Had progressive degenerative encephalopathy
13 Had near-drowning event in ice water with core temperature
≤32°C
8 Had additional cardiac arrest before randomization
6 Had condition in which direct skin-surface cooling was
contraindicated
5 Had chronic hypothermia with body temperature
consistently <37°C
4 Were cared for in neonatal ICU after cardiac arrest (would
not be admitted to pediatric ICU)
4 Were known to have sickle cell anemia
4 Had CNS tumor with ongoing chemotherapy or radiation
therapy
4 Had previously enrolled in THAPCA trials
1 Was participating in concurrent interventional study that
prevented effective use of targeted temperature therapy
475 Were eligible
180 Did not undergo randomization
29 Had families that were not approached for consent since
doctor thought participation inappropriate
19 Had families that were not approached for consent owing
to inadequate resources such as surface cooling unit in
current use
16 Had families that were not approached for consent owing
to other reasons
112 Had families that were approached for consent, but declined
to participate
4 Had families that consented, but child did not undergo
randomization
295 Underwent randomization
(ITT population)
Hypothermia

Normothermia

155 Were assigned
142 Were eligible for modified ITT primary analysis
(12 had baseline VABS-II score <70, 1 had no VABS-II
score and POPC or PCPC score ≥3)

140 Were assigned
128 Were eligible for modified ITT primary analysis
(11 had baseline VABS-II score <70, 1 had no VABS-II
score and POPC or PCPC score ≥3)
139 Received normothermia therapy
1 Received hypothermia therapy
4 In the modified ITT population,
including 2 who withdrew consent,
had unknown vital status at 1 yr
2 In the modified ITT population were
alive at 1 yr but 1-yr VABS-II score was
not obtained

152 Received hypothermia therapy
3 Received no treatment
4 In the modified ITT population had
unknown vital status at 1 yr

138 In the modified ITT population were included
in the primary analysis
151 In the ITT population were included in both
secondary analyses

n engl j med 372;20
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122 In the modified ITT population were included
in the primary analysis
136 In the ITT population were included in secondary
survival analysis
134 In the ITT population were included in secondary
analysis of change in VABS-II score from baseline
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provide the study with 85% power to detect a
20% treatment effect.
The efficacy analysis for the primary outcome
was performed with the use of a prespecified
modified intention-to-treat approach, excluding
children with poor neurobehavioral function
before cardiac arrest, as noted above. Secondary
efficacy outcomes were analyzed in all the children. Safety analyses were performed according
to the treatment received in treated patients
only. The primary outcome and 12-month mortality were compared between the treatment
groups with the use of a Cochran–Mantel–Haenszel
test stratified according to age category.
The change in the VABS-II score was analyzed
with the use of van Elteren’s modification of the
Mann–Whitney test,22 with stratification according to age category, treatment of death as the
worst outcome, and treatment of the lowest pos-

of
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sible VABS-II score at 1 year as the second worst
outcome. An alpha level of 0.05 was set for the
primary analysis, and an alpha level of 0.025 was
set for each of the two formal secondary analyses, with two-sided tests used in all instances.
The probability of survival to 1 year was evaluated by comparing survival curves over time between treatment groups with the use of a logrank test stratified according to age category. All
analyses were performed with the use of SAS
software, version 9.3 (SAS Institute).

R e sult s
Patients

Between September 1, 2009, and December 31,
2012, we identified 1355 patients who were
screened for eligibility and met the trial inclusion
criteria (Fig. 1). Of these patients, 475 were eli-

Table 1. Baseline Characteristics of the Patients before Randomization.*
Hypothermia Group
(N = 155)

Characteristic

Normothermia Group
(N = 140)

Demographic characteristics
Age — yr
Median

2.1

1.6

0.6–10.1

0.4–7.0

<2 yr

76 (49)

73 (52)

2 to <12 yr

48 (31)

45 (32)

≥12 yr

31 (20)

22 (16)

102 (66)

94 (67)

81 (52)

71 (51)

Lung or airway disease

33 (21)

34 (24)

Neurologic condition

30 (19)

19 (14)

Gastrointestinal disorder

19 (12)

22 (16)

Prenatal condition

15 (10)

22 (16)

Congenital heart disease

14 (9)

21 (15)

Other

34 (22)

37 (26)

Interquartile range
Age category — no. (%)

Male sex — no. (%)
Medical history — no. (%)
No preexisting medical condition
Preexisting medical condition

Characteristics of the cardiac arrest
Primary cause of the cardiac arrest — no. (%)
Respiratory event

111 (72)

102 (73)

Cardiovascular event

14 (9)

18 (13)

Other

11 (7)

4 (3)

Unknown
Bystander witnessed cardiac arrest — no./total no. (%)
Bystander performed CPR — no./total no. (%)

1902
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19 (12)

16 (11)

58/145 (40)

51/136 (38)

101/149 (68)

85/134 (63)
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Table 1. (Continued.)
Hypothermia Group
(N = 155)

Characteristic

Normothermia Group
(N = 140)

Initial rhythm noted by EMS or hospital — no. (%)
Asystole
Bradycardia

85 (55)

87 (62)

9 (6)

10 (7)

Pulseless electrical activity

25 (16)

18 (13)

Ventricular fibrillation or tachycardia

14 (9)

9 (6)

Unknown

22 (14)

16 (11)

Time from cardiac arrest to CPR in 82 patients — min
Median

3.0

Interquartile range

0.0–7.0

2.0
0.0–8.0

Duration of CPR in 186 patients — min
Median
Interquartile range
First hospital patient arrived at was the study hospital — no. (%)
Chest compressions still required at time of arrival at first
hospital — no./total no. (%)

23.0

28.0

15.0–35.0

19.0–45.0

45 (29)

43 (31)

97/152 (64)

100/137 (73)

No. of doses of epinephrine
Administered by EMS in 270 patients†
Median
Interquartile range

2.0

1.0

0.0–3.0

0.0–2.0

Administered at hospital in 289 patients†
Median
Interquartile range

1.0

2.0

0.0–3.0

0.0–4.0

All doses administered by EMS and at hospital in 265 patients
Median
Interquartile range

3.0

3.0

2.0–4.5

2.0–5.0

* CPR denotes cardiopulmonary resuscitation, and EMS emergency medical services.
† P<0.05 for the comparison between the two groups.

gible to enroll in the study. The families of 411 of
these patients were approached for consent, 299
families consented, and 295 patients underwent
randomization at 36 sites in the United States
and Canada (2 sites did not enroll any patients).
Of the patients who underwent randomization to
targeted temperature management, 155 were assigned to therapeutic hypothermia and 140 were
assigned to therapeutic normothermia. A total of
3 patients who were assigned to therapeutic hypothermia did not receive an intervention, and
1 patient assigned to therapeutic normothermia
received hypothermia therapy.
Of the 295 patients who underwent randomization, 13 in the hypothermia group and 12 in the
normothermia group were ineligible for the primary outcome analysis owing to baseline VABS-II
n engl j med 372;20

scores that were less than 70, or POPC or PCPC
scores that were 3 or higher. At 12 months, vital
status was not known in 4 patients in each group,
and 2 additional surviving children in the normothermia group did not undergo VABS-II testing (Fig. 1). Therefore, 260 patients had data
that could be evaluated for the primary outcome.
Characteristics at Baseline and Temperature
Intervention

The characteristics of the patients in the hypothermia group and those in the normothermia
group were similar at baseline (Table 1, and Table S1 in the Supplementary Appendix). The median age of the patients was 2 years; two thirds
of the patients were male. Bystanders witnessed
the cardiac arrest in 39% of the patients and pernejm.org
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Figure 2. Temperature of Patients during 120 Hours of Targeted Temperature
Management, According to Treatment Group.
The temperature curves show the means of all primary temperature readings
within each time interval (for example, all primary temperature readings from
22 to 26 hours after the initiation of treatment are counted in the category
“24 hours since initiation of treatment”). The I bars indicate ±2 SD from
the mean temperature within each time interval. Time points for normothermia are slightly shifted to prevent overlap. Temperatures recorded after
early termination of treatment are not included in this analysis.

formed cardiopulmonary resuscitation in 66% of
them. The initial rhythm was ventricular fibrillation or ventricular tachycardia in 8% of the patients. Baseline functional status based on the
VABS-II, PCPC, and POPC scores is shown in
Table S2 in the Supplementary Appendix.
The median time from the return of circulation to the initiation of treatment was 5.9 hours
(interquartile range, 5.2 to 6.7) in the hypothermia group and 5.8 hours (interquartile range,
5.0 to 6.4) in the normothermia group. Figure 2
shows the primary central (core) temperatures
recorded for the two groups. Additional information regarding temperature control is provided in the Supplementary Appendix.
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data, did not alter the primary-outcome result
(see the Supplementary Appendix).
The secondary outcome of change in the
VABS-II score from baseline to 12 months also
did not differ significantly between the two
groups (P = 0.13). The overall proportion of patients with 12-month VABS-II scores that did not
decrease by more than 15 points (1 SD) of their
baseline measurements was similar in the hypothermia group and the normothermia group
(14% and 13%) (Table 2).
Mortality among all patients who underwent
randomization and whose vital status was known
(287 of 295 patients [97%]) was assessed at 12
months. Survival at 1 year did not differ significantly between the groups (38% in the hypothermia group vs. 29% in the normothermia
group; relative likelihood, 1.29; 95% CI, 0.93 to
1.79; P = 0.13) (Table 2). Survival over time was
significantly longer with therapeutic hypothermia than with therapeutic normothermia (mean
survival, 149±14 days vs. 119±14 days; P = 0.04
for the comparison of survival between the two
treatment groups by means of the log-rank test)
(Fig. S1 in the Supplementary Appendix). The
primary cause of death was brain death or withdrawal of life-sustaining therapy owing to a poor
neurologic prognosis in the majority of patients
in the two groups (82% of the patients in the
hypothermia group and 79% of the patients in
the normothermia group) (Table S3 in the Supplementary Appendix).
Data on global cognitive functioning in survivors are shown in Table S4 in the Supplementary Appendix. Results of the Early Learning
Composite score from the Mullen Scales of Early
Learning23 did not differ significantly between
the survivors in the hypothermia group and those
in the normothermia group; there were also no
significant between-group differences in the IQ
score24 distributions on the Wechsler Abbreviated
Scale of Intelligence or in the combined categories from both the Mullen and the Wechsler tests.

Outcomes

The proportion of survivors with VABS-II scores
of 70 or more at 12 months was not significantly
different between the two groups (20% in the
hypothermia group vs. 12% in the normothermia group; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P = 0.14) (Table
2). Sensitivity analyses, including a per-protocol
analysis and analyses with imputation of missing
1904
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Safety

The incidences of infection, bleeding, and serious arrhythmias within 7 days after randomization were similar in the 153 patients who received
hypothermia therapy and the 139 who received
normothermia therapy (Table 3). Mortality at 28
days was also not significantly different in the
two groups (57% in the hypothermia group vs.
nejm.org
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Table 2. Primary and Secondary Outcomes.*
Hypothermia
Group

Outcome

Normothermia
Group

no./total no. (%)

Risk Difference

Relative Likelihood
(95% CI)

P Value

1.54 (0.86 to 2.76)

0.14†

percentage points (95% CI)

Primary outcome
Alive with VABS-II score ≥70 at 1 yr

27/138 (20)

15/122 (12)

87/138 (63)

88/122 (72)

16/138 (12)

11/122 (9)

7.3 (−1.5 to 16.1)

Detailed supportive analysis

0.14‡

Death
Disability
Profound§
Moderate-to-severe¶
Good functional status‖

8/138 (6)

8/122 (7)

27/138 (20)

15/122 (12)

57/151 (38)

39/136 (29)

Secondary outcomes
Alive at 1 yr

9.1 (−1.8 to 19.9)

1.29 (0.93 to 1.79)

1-yr change in VABS-II score from
baseline

0.13†
0.13**

Death
Lowest possible VABS-II score

94/151 (62)

97/134 (72)

6/151 (4)

1/134 (1)
15/134 (11)

Decrease in VABS-II score
>30 points

19/151 (13)

16–30 points

11/151 (7)

4/134 (3)

≤15 points or improved

21/151 (14)

17/134 (13)

* The primary outcome was evaluated in patients with a baseline Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70
or higher at 12 months (scores on the VABS-II range from 20 to 160, with higher scores indicating better function). The secondary outcomes were evaluated in all patients with available data. Denominators reported are for patients whose outcomes were known. CI denotes
confidence interval.
† The P value was calculated by means of the Cochran–Mantel–Haenszel test, with adjustment for age category.
‡ The P value was calculated by means of the Mann–Whitney test on the basis of the 1-year continuous VABS-II score, stratified according
to age category. Deceased patients and those with the lowest possible VABS-II score were assigned ranks of −2000 and −1000, respectively
(i.e., the worst possible scores).
§ Profound disability was defined as a VABS-II score of less than 45 or the lowest possible score.
¶ Moderate-to-severe disability was defined as a VABS-II score of 45 to 69.
‖ Good functional status was defined as a VABS-II score of 70 or higher.
** The P value was calculated by means of the Mann–Whitney test on the basis of the continuous change in VABS-II score, stratified according to age category. Deceased patients and those with the lowest possible VABS-II score were assigned ranks of −2000 and −1000, respectively (i.e., the worst possible scores).

67% in the normothermia group, P = 0.08). Additional data regarding adverse events are provided in Table S5 in the Supplementary Appendix.
Hypokalemia and thrombocytopenia occurred
more frequently in the hypothermia group, and
renal-replacement therapy was used more often
in the normothermia group.

Discussion
The THAPCA-OH trial evaluated the efficacy of
therapeutic hypothermia (targeted temperature
management at 33.0°C) and therapeutic normothermia (targeted temperature management at
36.8°C) to improve outcomes after out-of-hospital
n engl j med 372;20

cardiac arrest in children. There was no significant between-group difference in the primary
outcome of survival with a good neurobehavioral
outcome (VABS-II composite score of ≥70) at
12 months. The secondary outcome, the change
in the VABS-II score from baseline to 1 year, did
not differ between the groups; the proportion of
children with VABS-II scores that decreased no
more than 15 points (1 SD) from their baseline
scores was similar in the two groups. All-cause
mortality at 1 year also did not differ significantly between the two groups, although survival
analysis through 365 days showed a significant
difference in survival time in favor of therapeutic
hypothermia.
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Table 3. Safety Outcomes within 7 Days after Randomization and 28-Day Mortality.
Hypothermia
Group (N = 153)

Normothermia
Group (N = 139)

P Value*

83/153 (54)

74/138 (54)

0.92

Cryoprecipitate

13/153 (8)

12/137 (9)

0.94

Fresh-frozen plasma

50/153 (33)

41/138 (30)

0.59

Packed red cells or whole blood

65/153 (42)

59/137 (43)

0.92

Platelets

19/153 (12)

12/137 (9)

0.32

17/153 (11)

13/137 (9)

0.66

Asystole

6/153 (4)

5/137 (4)

0.91

Atrial (supraventricular tachycardia, atrial
flutter, junctional ectopic tachycardia)

4/153 (3)

2/137 (1)

0.53

Outcome
Blood-product use — no./total no. (%)
Any
Type

Arrhythmias — no./total no. (%)
Serious
Type

Pulseless electrical activity

1/153 (1)

0/137

0.53

Ventricular (sustained ventricular
tachycardia >30 sec, ventricular
fibrillation, torsades)

5/153 (3)

5/137 (4)

0.86

Other

7/153 (5)

2/137 (1)

0.14

70/153 (46)

54/137 (39)

0.28

Culture-proven infections
Any — no./total no. (%)
No. of infections

109

76

No. of days at risk

978

765

11.1 (9.2–13.4)

9.9 (7.8–12.4)

0.46†

87/153 (57)

93/139 (67)

0.08

Rate of infections/100 days (95% CI)†
All-cause mortality 28 days — no./total no. (%)

* P values for all comparisons, except where noted, are two-sided mid-P values, based on an exact likelihood-ratio test.

† Confidence intervals are exact two-sided 95% confidence intervals, and the P value is based on an exact test of homogeneity of event rates between the hypothermia group and the normothermia group, assuming that event data follow
Poisson distributions.

One important potential limitation of the
trial is that, on the basis of the observed confidence limits for treatment differences, a potentially important clinical benefit cannot be ruled
out despite the lack of a significant difference in
the primary outcome measure. A larger trial
might have detected or rejected a smaller intervention effect. Indeed, there was a significant
difference in survival time with therapeutic hypothermia, although this was a secondary outcome measure.
Other trial limitations should also be noted.
Caregivers and research staff in the ICU could
not be unaware of the treatment assignments of
the patients, although the primary outcome assessments were blinded. We could not rule out
the possibility of earlier death or determination
by clinical teams of futility in the normothermia
group. Patients in the hypothermia group may
1906
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have survived longer because prognostic assessments were delayed until normothermia was
achieved. For logistical reasons, we did not conduct a preclinical trial site phase-in or use only
high-enrolling sites; such strategies have been
suggested in other hypothermia trials.13,25-28
Our overall findings are consistent with those
of a previous clinical trial investigating the efficacy of therapeutic hypothermia (target temperature, 33°C) versus therapeutic normothermia
(target temperature, 36°C) in adult survivors of
out-of-hospital cardiac arrest.8 In contrast to the
earlier trials,4,5 in the recent trial involving
adults, fever was prevented in the normothermia
group through an active intervention similar to
that in our normothermia group.8 The duration
of temperature control, however, was much longer in our trial (120 hours vs. 36 hours). Moreover, the characteristics of our population of
nejm.org
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children with out-of-hospital cardiac arrest differed markedly from the population of adults
with out-of-hospital cardiac arrest, as expected.
The leading cause of cardiac arrest was a respiratory condition in 72% of our patients, as compared with a presumed cardiac cause in all patients in the recent trial involving adults.8 Our
trial also had a much lower proportion of patients with shockable rhythms (8% vs. 80%).8
One possible explanation for the difference
between the early trials of therapeutic hypothermia and the more recent studies is that controlled normothermia (which was used in the
more recent trials) may be beneficial in patients
with cardiac arrest. Fever commonly occurs after
hypoxic–ischemic brain injury.3,29-31 Initial trials
of therapeutic hypothermia for neonatal asphyxial encephalopathy and adult cardiac arrest
did not prevent fever in control groups.4,32-34 A
recent trial of cooling versus normal temperature control in neonatal patients at high risk for
neurologic injury who were receiving ECMO support showed no difference in outcome or adverse
effects.35 Studies of the usefulness of therapeutic hypothermia for traumatic brain injury in
children have not shown efficacy,36 and one
showed a trend toward higher mortality.13
Unanswered questions remain concerning
the potential role of targeted temperature management in children after cardiac arrest. Alternative durations of therapeutic hypothermia
temperature control (longer or shorter), different
depths of temperature control (higher or lower),
and a different therapeutic window for initiating
therapeutic hypothermia (shorter) are modifications that might be considered for future study.

Modification of inclusion and exclusion criteria
and a combination of targeted temperature
management with neuroprotective agents might
also be considered in future trials of treatment
involving children after cardiac arrest.37 We are
currently evaluating targeted temperature management in children after in-hospital cardiac
arrest (ClinicalTrials.gov number, NCT00880087);
this represents a pathophysiologically distinct
population, and the efficacy of the interventions
may differ.38
In conclusion, in comatose children who survive of out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic
normothermia, did not confer a significant
benefit with respect to survival with good functional outcome at 1 year. Survival at 12 months
did not differ significantly between the treatment groups.
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